New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
08:44 EDTACT, FRXActavis shares should be bought ahead of guidance, says Sterne Agee
After reevaluating its assumptions regarding the synergies that Actavis (ACT) can generate from its acquisition of Forest Labs (FRX), Sterne Agee raised its price target on Actavis to $250 from $230. The firm recommends buying Actavis ahead of guidance for the combined company ,which the firm expects to be provided in July. Sterne Agee keeps a Buy rating on Actavis.
News For ACT;FRX From The Last 14 Days
Check below for free stories on ACT;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
17:02 EDTACT, FRXActavis files to sell 843,085 ordinary shares
The offering is related to shares that may be issued upon the exercise of stock options granted under certain equity plans of Forest Laboratories to former employees or former directors of Forest.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use